How Viable Is The Future Of The “Traditional” CGM?
Executive Summary
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
You may also be interested in...
Ladies! Meet Movano: The Fashion-Forward Smart Ring Backed By Medical-Grade Accuracy
Movano expects to introduce its first smart ring, this one specifically for women, in the first half of 2023 in the US while it continues clinical trials to add medical parameters requiring FDA clearances, such as glucose and blood pressure.
Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.